Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥273,000 million, core operating profit of ¥46,000 million, core net profit for the year of ¥34,500 million and basic core earnings per share of ¥94.27. On IFRS basis, the company expects revenue of ¥273,000 million, operating profit of ¥32,000 million, net profit for the year of ¥22,400 million and basic earnings per share of ¥61.24.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,600 JPY | -0.81% | +3.53% | +13.84% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.84% | 3.84B | |
+31.06% | 682B | |
+30.35% | 586B | |
-3.42% | 364B | |
+18.02% | 327B | |
+4.27% | 285B | |
+15.53% | 240B | |
+10.16% | 209B | |
-8.14% | 203B | |
+8.12% | 165B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024